Search research articles
Contact Us
Filters
Showing results (111-120 of 127) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)
Lynne I Wagner, Fengmin Zhao, Fangxin Hong, et al.
The Journal of Experimental Medicine
|
September 21, 2005
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis
Suzana Marusic, Michael W Leach, Jeffrey W Pelker, et al.
Toxicologic Pathology
|
March 8, 2014
Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®)
Anne M Ryan, Sharon A Sokolowski, Chee-Keng Ng, et al.
Cancer Medicine
|
August 30, 2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial
Laurie E Steffen McLouth, Fengmin Zhao, Taofeek K Owonikoko, et al.
Journal of Neuroimmunology
|
October 3, 2008
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses
Suzana Marusic, Paresh Thakker, Jeffrey W Pelker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 21, 2017
Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839
Martin J Edelman, Chen Hu, Quynh-Thu Le, et al.
Regulatory Toxicology and Pharmacology : RTP
|
October 31, 2024
Opportunities and challenges for use of minipigs in nonclinical pharmaceutical development: Results of a follow-up IQ DruSafe survey
David O Clarke, Kaushik Datta, Kevin French, et al.
Journal of Neuroimmunology
|
December 22, 2006
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
Laura L Carter, Michael W Leach, Mihai L Azoitei, et al.
Regulatory Toxicology and Pharmacology : RTP
|
January 17, 2023
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
Helen Prior, Laura Andrews, Annick Cauvin, et al.
Regulatory Toxicology and Pharmacology : RTP
|
January 2, 2023
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
Hsiao-Tzu Chien, Helen Prior, Laura Andrews, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 127) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)
Lynne I Wagner, Fengmin Zhao, Fangxin Hong, et al.
The Journal of Experimental Medicine
|
September 21, 2005
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis
Suzana Marusic, Michael W Leach, Jeffrey W Pelker, et al.
Toxicologic Pathology
|
March 8, 2014
Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®)
Anne M Ryan, Sharon A Sokolowski, Chee-Keng Ng, et al.
Cancer Medicine
|
August 30, 2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial
Laurie E Steffen McLouth, Fengmin Zhao, Taofeek K Owonikoko, et al.
Journal of Neuroimmunology
|
October 3, 2008
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses
Suzana Marusic, Paresh Thakker, Jeffrey W Pelker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 21, 2017
Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839
Martin J Edelman, Chen Hu, Quynh-Thu Le, et al.
Regulatory Toxicology and Pharmacology : RTP
|
October 31, 2024
Opportunities and challenges for use of minipigs in nonclinical pharmaceutical development: Results of a follow-up IQ DruSafe survey
David O Clarke, Kaushik Datta, Kevin French, et al.
Journal of Neuroimmunology
|
December 22, 2006
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
Laura L Carter, Michael W Leach, Mihai L Azoitei, et al.
Regulatory Toxicology and Pharmacology : RTP
|
January 17, 2023
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
Helen Prior, Laura Andrews, Annick Cauvin, et al.
Regulatory Toxicology and Pharmacology : RTP
|
January 2, 2023
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
Hsiao-Tzu Chien, Helen Prior, Laura Andrews, et al.
Page
of 13